Synthesis and cytotoxic activities of some 2-arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell lines.
The synthesis of five 2-arylnaphtho[2,3-d]oxazole-4,9-dione derivatives was accomplished by refluxing 2-amino-3-bromo-1,4-naphthoquinone with appropriate benzoyl chloride analogs at elevated temperatures. In vitro anticancer evaluation of these compounds was performed on androgen-dependent, LNCaP, and androgen-independent, PC3, human prostate cancer cell lines. In general, these compounds displayed slightly stronger cytotoxicity on the androgen-dependent LNCaP than on the androgen-independent PC3 prostate cancer cell lines. The meta-substituted 2-(3-Chloro-phenyl)-naphtho[2,3-d]oxazole-4,9-dione (10) appear to display the best cytotoxicity on both cell lines with an IC(50) of 0.03 μM on LNCaP and 0.08 μM on PC3 after 5 days of exposure.
Department of Chemistry, Howard University, Washington, DC 20059, USA.
Yakini
Y
Brandy
Innocent
I
Ononiwu
Dolapo
D
Adedeji
Vonetta
V
Williams
Claudia
C
Mouamba
Yasmine
Y
Kanaan
Robert L
RL
Copeland
Dwayne A
DA
Wright
Ray J
RJ
Butcher
Samuel R
SR
Denmeade
Oladapo
O
Bakare
D000728:Androgens / Q000494:pharmacology*; D001583:Benzoxazoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D018360:Crystallography, X-Ray; D006801:Humans; D020128:Inhibitory Concentration 50; D008297:Male; D009285:Naphthoquinones / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D010080:Oxazoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology*
D000728:Androgens; D001583:Benzoxazoles; D009285:Naphthoquinones; D010080:Oxazoles
Bioorg Med Chem Lett. 2002 May 20;12(10):1375-8
11992780
Bioorg Med Chem. 2009 Jan 15;17(2):634-40
19101151
J Pharmacol Exp Ther. 2004 Apr;309(1):64-70
14718602
Mini Rev Med Chem. 2005 May;5(5):449-67
15892687
Bioorg Med Chem. 2005 Aug 15;13(16):4871-9
15921913
Pharmacol Res. 2005 Jun;51(6):553-60
15829436
Bioorg Med Chem. 2006 May 1;14(9):2880-6
16458007
Bioorg Med Chem. 2010 Mar 1;18(5):1899-909
20149966
Biochem Pharmacol. 2003 Apr 1;65(7):1061-75
12663042
Biochemistry. 2009 Jul 28;48(29):6963-74
19527023
Anticancer Res. 2009 Jan;29(1):191-9
19331150
Anticancer Res. 2007 May-Jun;27(3B):1537-46
17595773
Bioorg Med Chem Lett. 2006 Jan 1;16(1):171-5
16216500
J Med Chem. 2008 Mar 27;51(6):1706-18
18318466
Bioorg Med Chem. 2003 Jul 17;11(14):3165-70
12818679
Biochemistry. 2008 Jul 29;47(30):7838-45
18597479
Mini Rev Med Chem. 2007 May;7(5):481-9
17504183